Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Addex Therapeutics

< Previous 1 2 Next >
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
From Addex Therapeutics
Via GlobeNewswire
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Addex Therapeutics
Via GlobeNewswire
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
From Addex Therapeutics
Via GlobeNewswire
Addex’s Partner Discontinues ADX71149 development in Epilepsy
From Addex Therapeutics
Via GlobeNewswire
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
From Addex Therapeutics
Via GlobeNewswire
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
From Addex Therapeutics
Via GlobeNewswire
Addex Shareholders Approve All Resolutions at Annual General Meeting
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Convenes Annual General Meeting 2024
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
From Addex Therapeutics
Via GlobeNewswire
Addex to Present at Bio€quity Europe 2024
From Addex Therapeutics
Via GlobeNewswire
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
From Addex Therapeutics
Via GlobeNewswire
Addex to Present at the Swiss Biotech Day 2024
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
From Addex Therapeutics
Via GlobeNewswire
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
From Addex Therapeutics
Via GlobeNewswire
Addex to Present at the Bio-Europe Spring 2024 Conference
From Addex Therapeutics
Via GlobeNewswire
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
From Addex Therapeutics
Via GlobeNewswire
Addex to Present at the Swiss Equities Baader Conference
From Addex Therapeutics
Via GlobeNewswire
Addex to Present at Biotech Showcase™ 2024
From Addex Therapeutics
Via GlobeNewswire
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
From Addex Therapeutics
Via GlobeNewswire
Addex Creates Treasury Shares
From Addex Therapeutics
Via GlobeNewswire
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
Addex Convenes Extraordinary General Meeting
From Addex Therapeutics
Via GlobeNewswire
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
From Addex Therapeutics
Via GlobeNewswire
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
From Addex Therapeutics
Via GlobeNewswire
Addex Regains Nasdaq Listing Compliance
From Addex Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.